Sideroblastic anemia secondary prevention

Jump to navigation Jump to search

Sideroblastic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sideroblastic Anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sideroblastic anemia secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sideroblastic anemia secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sideroblastic anemia secondary prevention

CDC on Sideroblastic anemia secondary prevention

Sideroblastic anemia secondary prevention in the news

Blogs on Sideroblastic anemia secondary prevention

Directions to Hospitals Treating Sideroblastic anemia

Risk calculators and risk factors for Sideroblastic anemia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Associate Editor(s)-in-Chief: Nazia Fuad M.D.

Overview

Effective measures for the secondary prevention of sideroblastic anemia include iron chelators, Phlebotomy, regular liver function tests to assess for liver disease. Other measures include regular CBC in patients with MDS, cardiac monitoring, monitoring iron studies , and keeping ferriten level < 500 ng/ml.

Secondary Prevention

Effective measures for the secondary prevention of sideroblastic anemia include:[1]

References

  1. Ohba R, Furuyama K, Yoshida K, Fujiwara T, Fukuhara N, Onishi Y; et al. (2013). "Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)". Ann Hematol. 92 (1): 1–9. doi:10.1007/s00277-012-1564-5. PMC 3536986. PMID 22983749.

Template:WS Template:WH